Results 11 to 20 of about 2,111,387 (147)

Vaptans: A Narrative Review of Pharmacokinetics, Pharmacogenetics, and Clinical Applications [PDF]

open access: yesCells
Vaptans are non-peptide arginine vasopressin (AVP) receptor antagonists essential for modulating water homeostasis. This review evaluates their chemical evolution from peptide analogs to orally bioavailable molecules and summarizes the pharmacokinetic ...
Martyna Lica-Miler   +6 more
doaj   +2 more sources

Adverse Event Reporting Patterns Associated with Concomitant Use of 5-HT3 and NK-1 Receptor Antagonists: A Large-Scale Spontaneous-Reporting Analysis [PDF]

open access: yesPharmaceuticals
Background/Objectives: Chemotherapy-induced nausea and vomiting (CINV) is common and compromises quality of life and adherence. 5-HT3 receptor antagonists (RAs) and NK-1 RAs are cornerstones, yet adverse event patterns associated with their concomitant ...
Ruiqi Zhao   +7 more
doaj   +2 more sources

Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH) [PDF]

open access: yesEuropean Journal of Clinical Pharmacology, 2011
Arginine vasopressin (AVP) is the major physiological regulator of renal water excretion and blood volume. The AVP pathways of V(1a)R-mediated vasoconstriction and V(2)R-induced water retention represent a potentially attractive target of therapy for edematous diseases.
Gassanov, Natig   +5 more
openaire   +4 more sources

Vasopressin and a Nonpeptide Antidiuretic Hormone Receptor Antagonist (OPC-31260)

open access: yesBlood Pressure, 1994
The development of nonpeptide orally active AVP analogues has provided a new tool with which to assess the physiological and pathophysiological role of vasopressin (AVP). We have previously characterised the nonpeptide vasopressin V1 receptor antagonist OPC-21268, and now report the in vitro characterisation of the nonpeptide V2 receptor antagonist OPC-
Louise Burrell   +2 more
exaly   +3 more sources

Metabolic effects of vasopressin in pathophysiology of diabetic kidney disease

open access: yesFrontiers in Endocrinology, 2023
The diabetic kidney disease (DKD) is the major cause of the chronic kidney disease (CKD). Enhanced plasma vasopressin (VP) levels have been associated with the pathophysiology of DKD and CKD.
Svetlana Lebedeva   +7 more
doaj   +1 more source

Clinical Implication of the Antidiuretic Hormone (ADH) Receptor Antagonist Mozavaptan Hydrochloride in Patients with Ectopic ADH Syndrome [PDF]

open access: yesJapanese Journal of Clinical Oncology, 2010
Ectopic antidiuretic hormone syndrome is a medical emergency characterized by dilutional hyponatremia. Clinical effectiveness of the vasopressin V2 receptor antagonist mozavaptan was evaluated in 16 patients. In short-term (7-day) treatment with the drug, serum sodium concentration (mean ± standard deviation) significantly (P = 0.002) increased from ...
Ken, Yamaguchi   +9 more
openaire   +2 more sources

Successful Long-Term Treatment of Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion with Satavaptan (SR121463B), an Orally Active Nonpeptide Vasopressin V2-Receptor Antagonist [PDF]

open access: yesClinical Journal of the American Society of Nephrology, 2006
The effects of satavaptan (SR121463B), a novel long-acting orally active vasopressin V(2)-receptor antagonist, were investigated in patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). In the first part of this randomized, double-blind study, 34 patients first were treated with satavaptan (versus placebo) for up to 5 d ...
Alain, Soupart   +6 more
openaire   +2 more sources

Evidence for a Prehypertensive Water Dysregulation Affecting the Development of Hypertension: Results of Very Early Treatment of Vasopressin V1 and V2 Antagonism in Spontaneously Hypertensive Rats

open access: yesFrontiers in Cardiovascular Medicine, 2022
In addition to long-term regulation of blood pressure (BP), in the kidney resides the initial trigger for hypertension development due to an altered capacity to excrete sodium and water.
Ignazio Verzicco   +17 more
doaj   +1 more source

ALTERATIONS IN RENAL HEMODYNAMICS AND ANTIDIURETIC HORMONE RELEASE FOLLOWING ACTIVATION OF THE VOLUME RECEPTOR MECHANISM IN THE DOG.

open access: yes, 1959
ALTERATIONS IN RENAL HEMODYNAMICS AND ANTIDIURETIC HORMONE RELEASE FOLLOWING ACTIVATION OF THE VOLUME RECEPTOR MECHANISM IN THE ...
ROBERT ALAN. BARATZ (7974779)
core   +4 more sources

Home - About - Disclaimer - Privacy